



FONDAZIONE MICHELANGELO
avanzamento dello studio e cura dei tumori

XIII MICHELANGELO SEMINAR

October 25, 2013
Milan, Hilton Hotel
Via Galvani, 12

Preliminary Program

h 13.00 - 19.00

FACULTY

- **Leisha Ann Emens**
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Hospital, Baltimore, USA
- **Luca Gianni**
Ospedale San Raffaele IRCCS, Milan, Italy
- **Thomas Karn**
Goethe - Universität Frankfurt am Main, Frankfurt, Germany
- **Christos Sotiriou**
Jules Bordet Institute, Bruxelles, Belgium
- **John Stagg**
University of Montreal, Canada

Breast cancer, the immune system and new immunotherapeutic opportunities

The interplay between the immune system and cancer has always attracted the focus of interest of immunologists. The ability of many tumors to fool the immune system and evade immune surveillance has explanation in specific mechanisms and regulations. New targets of therapy have been identified, and with the targets the availability of new drugs that have progressively attracted the interest of oncologists. The involvement of the immune system in the prognosis and therapeutic outcome of breast cancer is now becoming apparent, especially in triple negative and in HER2 overexpressing tumors. The role of tumor infiltration, of adaptive immune mechanisms and of immune checkpoints is emerging as one of the key new elements that explain the success or failure of conventional therapy and indicate the need to also control the immune response to foster the best benefit to breast cancer patients. In this XIII Seminar the Fondazione Michelangelo has invited key experts in the field of cancer immunotherapy to address the basic elements of emerging evidence involving the immune system with cancer prognosis, to report on the immune regulation of the response to conventional therapies, and to discuss how to implement new drugs such anti-immune check points in the treatment of breast cancer.

Endorsements






FONDAZIONE MICHELANGELO
avanzamento dello studio e cura dei tumori

XIII
MICHELANGELO
SEMINAR

Preliminary Program

- *Welcome address and introductory notes*
- *Promising immunotherapies for HER2+ and triple negative breast cancer*
J. Stagg, Montreal, Canada
- *The prognostic value of immune infiltration in breast cancer: any clinical utility for decision making?*
T. Karn, Frankfurt, Germany
- *The predictive value of the immune infiltration: any clinical utility for tailoring chemotherapy?*
C. Sotiriou, Bruxelles, Belgium
- *Immune regulation as potential mechanism of resistance to HER2-targeted therapy in breast cancer: clinical implication for new drug development*
Luca Gianni, Milano, Italy
- *Cancer immunotherapy: the benefit of targeting immune-checkpoints*
L.A. Emens, Baltimore, USA
- *General discussion and conclusion*

General information

- **Seminar Venue**
Milan Hilton Hotel (walking distance from Milan Central Station)
Via Galvani 12 - 20124 Milan (Italy)
Meeting room: Ballroom (ground floor)
 M2 - M3 Central Station
- **CME Accreditation** for the competent bodies (4,5 credits – n. 210/72512)
- **Official Language**
The official language will be English. Simultaneous translation will be provided
- **Application**
Attendance is free of charge, however application is compulsory.
Please send the application form to michelangelo@newaurameeting.it until 18th October 2013
- **Accommodation**
To require hotel accommodation in Milan, please fill in the registration form in attach; for further information, contact the Organizing Secretary to michelangelo@newaurameeting.it

Scientific Secretariat

- **Giampaolo Bianchini**
Ospedale San Raffaele IRCCS, Milan, Italy
bianchini.giampaolo@hsr.it
- **Angelica Fasolo**
Ospedale San Raffaele IRCCS, Milan, Italy
fasolo.angelica@hsr.it

Organizing Secretariat

- New Aurameeting Srl
Via Rocca d'Anfo, 7- 20161 Milan, Italy
Phone: +39 02 66203390
Fax: +39 02 66200418
E-mail: michelangelo@newaurameeting.it
www.newaurameeting.it